Elanco Animal Health (NYSE:ELAN – Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Elanco Animal Health to announce earnings of $0.2028 per share and revenue of $1.21 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the business posted $0.26 EPS. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. On average, analysts expect Elanco Animal Health to post $1.13 EPS for the current fiscal year and $1.28 EPS for the next fiscal year.
Elanco Animal Health Price Performance
Shares of NYSE:ELAN opened at $24.59 on Wednesday. The business has a 50-day simple moving average of $23.13 and a two-hundred day simple moving average of $23.82. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The firm has a market cap of $12.29 billion, a price-to-earnings ratio of -59.99, a price-to-earnings-growth ratio of 2.14 and a beta of 1.73. Elanco Animal Health has a fifty-two week low of $19.40 and a fifty-two week high of $27.98.
Analysts Set New Price Targets
ELAN has been the topic of several recent analyst reports. Jefferies Financial Group cut shares of Elanco Animal Health from a “buy” rating to a “hold” rating and reduced their price objective for the company from $31.00 to $24.00 in a research report on Tuesday, October 20th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. UBS Group increased their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Finally, The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They set a “buy” rating and a $32.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.33.
View Our Latest Stock Analysis on ELAN
Insider Transactions at Elanco Animal Health
In other news, Director Paul Herendeen purchased 10,000 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. This represents a 9.83% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shiv O’Neill acquired 3,998 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were acquired at an average price of $23.58 per share, with a total value of $94,272.84. Following the acquisition, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 63,198 shares of company stock worth $1,473,109. Insiders own 1.14% of the company’s stock.
About Elanco Animal Health
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.
The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.
Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.
Featured Articles
- Five stocks we like better than Elanco Animal Health
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
